Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Manufacture Small Molecules

Is Biopharma Ready to Say Goodbye to Batches?

Biopharmaceuticals are perhaps the most complex of all high-tech products, yet the most fundamental aspects of their manufacture have remained unchanged for decades. Most other modern industries have adopted continuous manufacturing (1), exemplified by the automobile assembly lines Henry Ford introduced over 100 years ago, petroleum refineries and newer steel mills, which run non-stop. In contrast, nearly all biopharmaceutical product manufacturing still involves batch processes.

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Authors

Ronald A. Rader

Senior Research Director at BioPlan Associates, Inc, Rockville, Maryland, USA.


Eric S. Langer

President and Managing Partner at BioPlan Associates, Inc, Rockville, Maryland, USA.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register